©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Orthop. Sep 18, 2016; 7(9): 527-538
Published online Sep 18, 2016. doi: 10.5312/wjo.v7.i9.527
Published online Sep 18, 2016. doi: 10.5312/wjo.v7.i9.527
Management of Ewing sarcoma family of tumors: Current scenario and unmet need
Bivas Biswas, Sameer Bakhshi, Department of Medical Oncology, Dr.B.R.A.I.R.C.H, All India Institute of Medical Sciences, New Delhi 110029, India
Author contributions: Biswas B performed the literature search, critical analysis, wrote the paper recorded the audio core tip; Bakhshi S reviewed and edited the paper and done the critical analysis.
Conflict-of-interest statement: No potential conflicts of interest to declare for each author.
Correspondence to: Dr. Bivas Biswas, Assistant Professor, Department of Medical Oncology, Dr.B.R.A.I.R.C.H, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India. bivasbiswas@gmail.com
Telephone: +91-98-30922005 Fax: +91-11-26588663
Received: April 27, 2016
Peer-review started: April 28, 2016
First decision: June 16, 2016
Revised: June 21, 2016
Accepted: July 11, 2016
Article in press: July 13, 2016
Published online: September 18, 2016
Processing time: 137 Days and 10 Hours
Peer-review started: April 28, 2016
First decision: June 16, 2016
Revised: June 21, 2016
Accepted: July 11, 2016
Article in press: July 13, 2016
Published online: September 18, 2016
Processing time: 137 Days and 10 Hours
Core Tip
Core tip: Ewing sarcoma family tumors are a heterogeneous and aggressive group of disease of bone and soft tissue in childhood. The outcome has improved with introduction of chemotherapy and multimodality management. But, the prognosis of patients with metastatic disease is dismal. Novel targeted therapies are investigational and may offer some hope in future, especially in metastatic setting. In this review we have discussed current treatment modality, prognostic factors, ongoing trials and novel investigational therapies.